Which endpoints are important to the G-BA and IQWiG?
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:
Category: Early benefit assessments
Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
The G-BA will collaborate on joint EU HTAs
In July 2021, we had heard that the G-BA had agreed to joint EU HTAs coming to Germany. Now, on 14 December
The G-BA increases the fees for consultations
Manufacturers of drugs or medical devices can apply for a consultation meeting with the G-BA before submitting a dossier. This consultation offers
Prof. Dr. Karl Lauterbach is the new German health minister
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot